Pharma BD Deal Intelligence

Acino International AG / Allecra Therapeutics

2024 · Licensing/Option · Complete

Allecra Therapeutics granted Acino exclusive rights to commercialize EXBLIFEP (cefepime/enmetazobactam) across the six Gulf Cooperation Council states and South Africa under a concurrent exclusive licensing and supply agreement effective 12 June 2024. EXBLIFEP is approved by the FDA (February 2024) and the European Commission (March 2024) for complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia and associated bacteremia; financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals